Gender Difference in the Effects of COVID-19 Pandemic on Mechanical Reperfusion and 30-Day Mortality for STEMI: Results of the ISACS-STEMI COVID-19 Registry.
COVID-19
ST-segment elevation myocardial infarction
gender
percutaneous coronary intervention
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
23 Jan 2023
23 Jan 2023
Historique:
received:
18
12
2022
revised:
04
01
2023
accepted:
17
01
2023
entrez:
11
2
2023
pubmed:
12
2
2023
medline:
12
2
2023
Statut:
epublish
Résumé
Several reports have demonstrated the impact of the COVID-19 pandemic on the management and outcome of patients with ST-segment elevation myocardial infarction (STEMI). The aim of the current analysis is to investigate the potential gender difference in the effects of the COVID-19 pandemic on mechanical reperfusion and 30-day mortality for STEMI patients within the ISACS-STEMI COVID-19 Registry. This retrospective multicenter registry was performed in high-volume primary percutaneous coronary intervention (PPCI) centers on four continents and included STEMI patients undergoing PPCIs in March-June 2019 and 2020. Patients were divided according to gender. The main outcomes were the incidence and timing of the PPCI, (ischemia time ≥ 12 h and door-to-balloon ≥ 30 min) and in-hospital or 30-day mortality. We included 16683 STEMI patients undergoing PPCIs in 109 centers. In 2020 during the pandemic, there was a significant reduction in PPCIs compared to 2019 (IRR 0.843 (95% CI: 0.825-0.861, The COVID-19 pandemic had a significant impact on the treatment of patients with STEMI, with a 16% reduction in PPCI procedures similarly observed in both genders. Furthermore, we observed significantly increased in-hospital and 30-day mortality rates during the pandemic only among females.
Sections du résumé
BACKGROUND
BACKGROUND
Several reports have demonstrated the impact of the COVID-19 pandemic on the management and outcome of patients with ST-segment elevation myocardial infarction (STEMI). The aim of the current analysis is to investigate the potential gender difference in the effects of the COVID-19 pandemic on mechanical reperfusion and 30-day mortality for STEMI patients within the ISACS-STEMI COVID-19 Registry.
METHODS
METHODS
This retrospective multicenter registry was performed in high-volume primary percutaneous coronary intervention (PPCI) centers on four continents and included STEMI patients undergoing PPCIs in March-June 2019 and 2020. Patients were divided according to gender. The main outcomes were the incidence and timing of the PPCI, (ischemia time ≥ 12 h and door-to-balloon ≥ 30 min) and in-hospital or 30-day mortality.
RESULTS
RESULTS
We included 16683 STEMI patients undergoing PPCIs in 109 centers. In 2020 during the pandemic, there was a significant reduction in PPCIs compared to 2019 (IRR 0.843 (95% CI: 0.825-0.861,
CONCLUSIONS
CONCLUSIONS
The COVID-19 pandemic had a significant impact on the treatment of patients with STEMI, with a 16% reduction in PPCI procedures similarly observed in both genders. Furthermore, we observed significantly increased in-hospital and 30-day mortality rates during the pandemic only among females.
Identifiants
pubmed: 36769546
pii: jcm12030896
doi: 10.3390/jcm12030896
pmc: PMC9918240
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Am Coll Emerg Physicians Open. 2020 Nov 23;1(6):1168-1176
pubmed: 33363285
Am Heart J. 2004 Nov;148(5):852-6
pubmed: 15523317
Circ J. 2021 Jan 25;85(2):139-149
pubmed: 33162491
Atherosclerosis. 2013 Sep;230(1):12-6
pubmed: 23958246
Am J Cardiovasc Dis. 2020 Oct 15;10(4):506-513
pubmed: 33224602
Circulation. 2020 Jun 16;141(24):2035-2037
pubmed: 32352318
J Am Coll Cardiol. 2020 Jun 9;75(22):2871-2872
pubmed: 32283124
Eur Heart J. 2020 Jun 7;41(22):2083-2088
pubmed: 32412631
J Am Coll Cardiol. 2020 Nov 17;76(20):2321-2330
pubmed: 33183506
Circulation. 2020 Jun 23;141(25):2113-2116
pubmed: 32352306
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
J Am Coll Cardiol. 2020 Sep 15;76(11):1318-1324
pubmed: 32828614
Cardiovasc Res. 2002 Feb 15;53(3):672-7
pubmed: 11861038
Lancet Respir Med. 2020 Apr;8(4):e20
pubmed: 32171067
Am J Cardiol. 2013 Apr 1;111(7):936-40
pubmed: 23332594
Circulation. 2004 Mar 16;109(10):1223-5
pubmed: 15007008
Front Endocrinol (Lausanne). 2014 Jan 09;4:201
pubmed: 24409169
Lancet Healthy Longev. 2021 May;2(5):e283-e289
pubmed: 36098135
Biomolecules. 2021 Dec 24;12(1):
pubmed: 35053169
Am J Cardiol. 2022 Mar 1;166:9-17
pubmed: 34969509
J Infect. 2020 Aug;81(2):282-288
pubmed: 32479771
J Cardiovasc Med (Hagerstown). 2022 Apr 1;23(4):234-241
pubmed: 35081074
Vascul Pharmacol. 2021 Oct;140:106897
pubmed: 34274529
Cardiovasc Diabetol. 2020 Dec 18;19(1):215
pubmed: 33339541
J Thromb Thrombolysis. 2010 Oct;30(3):342-6
pubmed: 20213259
Clin Infect Dis. 2021 Dec 6;73(11):e4208-e4213
pubmed: 32173725
J Thromb Thrombolysis. 2021 Oct;52(3):797-807
pubmed: 33847862
Scand J Public Health. 2022 Aug;50(6):748-755
pubmed: 34933630
Biol Sex Differ. 2020 May 25;11(1):29
pubmed: 32450906
Trends Cardiovasc Med. 2021 Apr;31(3):135-140
pubmed: 33338636
J Clin Med. 2021 Nov 29;10(23):
pubmed: 34884341
BMC Cardiovasc Disord. 2021 Jan 7;21(1):23
pubmed: 33413093
Circ Cardiovasc Qual Outcomes. 2020 Apr;13(4):e006631
pubmed: 32182131